Cellenis Derma PRP
Cellenis® Derma PRP is a cutting-edge, novel technique derived from completely natural materials with minimal to no risk of allergic reaction.
Uniting the exceptional attributes of Cellenis® PRP for tissue regeneration with the advancements of Cellenis Derma PRP, an extended-release natural biologic derived from the patient's DNA, to offer an immediate volumizing effect and promote long-lasting dermal health.
Cellenis® Derma PRP provides immediate volumizing harnessing the patient’s own DNA. The treatment is performed in office with a small blood sample taken from the patient. It is  safe, effective, versatile, non-allergenic procedure, and offers virtually no downtime or side effects. It is a quick and simple treatment that can be performed alone or in combination with many aesthetic services.
How Cellenis Derma PRP Works
Blood is drawn and processed  similar to Cellenis® PRP.  The Cellenis® Derma PRP is further processed to  break the linkages or hydrogen bonds within its protein molecules.  Proteins are then restructured in a more densely organized, mesh-like scaffolding with extended reabsorption properties.Â
Cellenis® Derma PRP can be used within 4 hours of processing.  It is a completely autologous material with minimal to no risk of product of allergic reaction.Â
- Platelet Poor Plasma (PPP) is extracted from the prepared Platelet Rich Plasma (PRP)Â
- The PPP which contains 60% albumin is processed in ordered to denature the linkages or hydrogen bonds within the protein molecules (1)Â
- The proteins are refined into a more densely organized mesh-like structure with extended resorption properties for up to 4–6 months (2)Â
- The restructured properties allow for a slow, extended-release of platelet derived growth factors.  This induces neocollagenesis and enhances skin radiance & revitalization.Â
Enhance Your Beauty Naturally
- Natural biologic created for the patient’s own bloodÂ
- Simple, Quick, Small draw. Easy to use
- Comfortable, easy treatment.Â
- Non-Allergenic and safe for a wider range of patients, including immunocompromised individuals